

Open Peer Review on Qeios

TRK Inhibitor AZD6918

National Cancer Institute

Source

National Cancer Institute. <u>TRK Inhibitor AZD6918</u>. NCI Thesaurus. Code C80491.

An orally available liquid suspension containing the tropomyosin receptor kinase (Trk) inhibitor AZD6918 with potential antineoplastic activity. AZD6918 binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, and may eventually result in cell cycle arrest and apoptosis of tumor cells that express Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.

Qeios ID: CJLS1A · https://doi.org/10.32388/CJLS1A